Response to ‘Feasibility of tailored treatment based on risk stratification in patients with early rheumatoid arthritis’

Por Vastesaeger, Nathan, Fautrel, Bruno, Smolen, Josef
Publicado no Arthritis Res Ther (2015)

Response to the commentary 'Pooled indices to measure rheumatoid arthritis activity: a good reflection of the physician's mind'

Por Vander Cruyssen, Bert, Durez, Patrick, Westhovens, Rene, Vastesaeger, Nathan, Geldhof, Anja, De Keyser, Filip
Publicado em 2006

Infliximab plus methotrexate is superior to methotrexate alone in the treatment of psoriatic arthritis in methotrexate-naive patients: the RESPOND study

Por Baranauskaite, Asta, Raffayová, Helena, Kungurov, NV, Kubanova, Anna, Venalis, Algirdas, Helmle, Laszlo, Srinivasan, Shankar, Nasonov, Evgeny, Vastesaeger, Nathan
Publicado em 2011

Effectiveness and Safety of Infliximab in Two Cases of Severe Chondrocalcinosis: Nine Years of Follow-Up

Por Bruges-Armas, Jácome, Bettencourt, Bruno F., Couto, Ana R., Lima, Manuela, Rodrigues, Ana M., Vastesaeger, Nathan, Brown, Matthew A.
Publicado no Case Rep Rheumatol (2014)

The epidemiology of ankylosing spondylitis and the commencement of anti‐TNF therapy in daily rheumatology practice

Por Cruyssen, Bert Vander, Ribbens, Clio, Boonen, Annelies, Mielants, Herman, de Vlam, Kurt, Lenaerts, Jan, Steinfeld, Serge, Van den Bosch, Filip, Dewulf, Lode, Vastesaeger, Nathan
Publicado em 2007

Efficacy and safety of golimumab as add-on therapy to disease-modifying antirheumatic drugs: results of the GO-MORE study

Por Combe, Bernard, Dasgupta, Bhaskar, Louw, Ingrid, Pal, Sarvajeet, Wollenhaupt, Jürgen, Zerbini, Cristiano A F, Beaulieu, Andre D, Schulze-Koops, Hendrik, Durez, Patrick, Yao, Ruji, Vastesaeger, Nathan, Weng, Haoling H
Publicado em 2014

Predicting the outcome of ankylosing spondylitis therapy

Por Vastesaeger, Nathan, van der Heijde, Désirée, Inman, Robert D, Wang, Yanxin, Deodhar, Atul, Hsu, Benjamin, Rahman, Mahboob U, Dijkmans, Ben, Geusens, Piet, Vander Cruyssen, Bert, Collantes, Eduardo, Sieper, Joachim, Braun, Jürgen
Publicado em 2011

Four-year follow-up of infliximab therapy in rheumatoid arthritis patients with long-standing refractory disease: attrition and long-term evolution of disease activity

Por Cruyssen, Bert Vander, Van Looy, Stijn, Wyns, Bart, Westhovens, Rene, Durez, Patrick, Van den Bosch, Filip, Mielants, Herman, De Clerck, Luc, Peretz, Ann, Malaise, Michel, Verbruggen, Leon, Vastesaeger, Nathan, Geldhof, Anja, Boullart, Luc, De Keyser, Filip
Publicado em 2006

DAS28 best reflects the physician's clinical judgment of response to infliximab therapy in rheumatoid arthritis patients: validation of the DAS28 score in patients under infliximab...

Por Vander Cruyssen, Bert, Van Looy, Stijn, Wyns, Bart, Westhovens, Rene, Durez, Patrick, Van den Bosch, Filip, Veys, Eric M, Mielants, Herman, De Clerck, Luc, Peretz, Anne, Malaise, Michel, Verbruggen, Leon, Vastesaeger, Nathan, Geldhof, Anja, Boullart, Luc, De Keyser, Filip
Publicado em 2005

Prediction of remission and low disease activity in disease-modifying anti-rheumatic drug-refractory patients with rheumatoid arthritis treated with golimumab

Por Vastesaeger, Nathan, Kutzbach, Abraham Garcia, Amital, Howard, Pavelka, Karel, Lazaro, María Alicia, Moots, Robert J., Wollenhaupt, Jürgen, Zerbini, Cristiano A. F., Louw, Ingrid, Combe, Bernard, Beaulieu, Andre, Schulze-Koops, Hendrik, Dasgupta, Bhaskar, Fu, Bo, Huyck, Susan, Weng, Haoling H., Govoni, Marinella, Durez, Patrick
Publicado no Rheumatology (Oxford) (2016)